Chiang Mai University

cmu.ac.th

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

117

Active

13

Phase 3

19

Total enrollment

23,046

Pipeline matrix

Showing 9 of 9 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Maternal TdaP2gen vaccine1
Infant Acellular Pertussis-containing Vaccine1
Infant Whole-cell Pertussis-containing Vaccine1
Colistin Sodium Methanesulfonate1
Colistin Sodium Methanesulfonate plus Fosfomycin1
Furosemide1
Inactivated hepatitis A vaccine1
MPFF1
Aescin in Horse Chestnut2

Next readouts

  • 2025-03
  • 2025-06-22
  • 2025-07
  • 2028-12-31
  • 2029-12-31

Top conditions

  • Vaccine-Preventable Diseases4
  • Mild Cognitive Impairment3
  • Hepatitis A3
  • HIV Infection3
  • Hypertension3
  • Peritoneal Dialysis3
  • Hepatitis B3
  • Acute Kidney Injury3

Frequently asked questions about Chiang Mai University

How many clinical trials does Chiang Mai University have on ClinicalTrials.gov?
Chiang Mai University is listed as the lead sponsor on 117 clinical trials in ClinicalTrials.gov, 13 of which are currently active (recruiting, enrolling, or ongoing).
How many of Chiang Mai University's trials are in Phase 3?
19 of Chiang Mai University's trials are in Phase 3, spread across 9 active drug programs.
What therapeutic areas does Chiang Mai University focus on?
Chiang Mai University's most-studied conditions on ClinicalTrials.gov are Vaccine-Preventable Diseases, Mild Cognitive Impairment, Hepatitis A, HIV Infection, Hypertension.
When are Chiang Mai University's next clinical trial readouts?
Chiang Mai University has 5 upcoming primary-completion readouts tracked here; the soonest is “Colistin Monotherapy vs Colsitin-fosfomycine in CRAB Infection”, expected around 2025-03.